more_reports

Dr. Andre Uddin

Research Capital Corporation

Image: Dr. Andre Uddin

Andre Uddin is managing director, healthcare research at Mackie Research. Uddin has over 20 years of global experience in the investment, biotechnology and pharmaceutical industries, most recently as strategic advisor and consultant to a number of leading TSX and LSE companies. He was also Vice-President of Strategic Development for a NASDAQ-listed biopharmaceutical company. Uddin began his career in the brokerage community, where he was a top-ranked analyst specializing in coverage of the Canadian biotechnology, pharmaceutical and medical device sectors at National Bank Financial, Research Capital and Merrill Lynch Canada. Uddin holds an Honours Bachelor of Science in Biochemistry from the University of Toronto, and a Ph.D in Biological Chemistry from McGill University. Uddin's bio-organic research has been widely published in many scientific journals, including the Journal of American Chemical Society, Biochemistry and Nucleic Acid Research.

Recent Articles

Pharma Co. Primed for Future Business 01/25/2024

Analysts at Research Capital believe that Knight Therapeutics Inc. is primed to conduct future business development.


Recent Quotes

"Positive Phase 2a data were achieved with AGN's ifenprodil."

— Dr. Andre Uddin, Research Capital Corporation (11/30/22)
more >

more quotes

"It would be logical for AGN to develop ifenprodil for two indications."

— Dr. Andre Uddin, Research Capital Corporation (7/28/22)
more >

"In the Phase 2a trial in IPF, AGN's ifenprodil hit its endpoint."

— Dr. Andre Uddin, Research Capital Corporation (7/18/22)
more >

fewer comments


Due to permission requirements, not all quotes are shown.